PfizerAlbert Bourla, CEO of the company, stated Tuesday that the U.S. government had ordered sufficient Covid-19 vaccine doses for every child within the country. This was in response to a Centers for Disease Control Panel. meetsTo decide whether or not to authorize shots for children aged 5-11 years old

The U.S. government placed orders with us to cover every child in the country. Bourla stated that the supplies will be available and that it will hopefully benefit a lot more children,” Bourla told CNBC’s “5”.The Exchange“

The Food and Drug Administration approved Friday Pfizer vaccines to be given to children aged 5-11 years old. The Advisory Committee on Immunization practices of the CDC reviewed data on Tuesday before deciding whether or not to recommend shots for this age group. Rochelle Wallace, Director at CDC could have to consider the recommendations of this committee before deciding whether or not to distribute vaccines.

Walensky should act quickly to implement the recommended recommendation of the advisory committee so that kids can begin their shots Tuesday evening. Pfizer vaccines to children 12-15 years old were approved by the CDC in May. It was only hours after the advisory panel recommended them.

Bourla stated that parents who send their kids to daycare or school have experienced anxiety as they were not vaccinated.

While children have been responsible for 16.6% in Covid cases in America, they have also remained within the lower single-digit percentile in Covid hospitalizations across the 24 reporting states. according toThe American Academy of Pediatrics.

According to CDC dataCovid is the leading cause of death in America, with 652 deaths since the beginning of the pandemic.

The AAP website states that “At the moment, it seems that severe illness caused by Covid-19 among children is rare.” It is urgent to gather more data about… how the virus might harm the long-term, physical health of infected kids.”

Bourla stated that children aged 5-11 years old will be given a lower dose of the mRNA based vaccines than those under 5, and even less for kids younger than 5. Bourla indicated that while trials for kids under 5 are continuing, he anticipates the Covid vaccine to be authorized in 2022.

Pfizer has developed an antiviral Covid pill that is similar in design to one created by pharmaceutical competitor MerckRidgeback Biotherapeutics is Ridgeback’s partner. Merck internal data shows that Covid treatment can reduce the chance of death and hospitalization by half in patients at high risk.

Bourla expressed his wish for Merck success in getting regulatory approval. He said that the world requires more treatment options. Pfizer is currently conducting three trials to evaluate its Covid therapy, he said.

Bourla stated that “our studies are continuing” and that a report on efficacy will be available before the year ends.

He stated that if the studies prove positive, and they have high efficacy we approved an investment in excess of one billion dollars late this summer. If we succeed, there will be quantities this year.

Bourla’s comments came after Pfizer posted stronger-than-expectedQuarterly reports were earlier in the day. Company also increased its Covid vaccine sales guidance for full year by 7.5%

Bourla stated that Pfizer can produce 4 billion vaccine doses in the next year. The company also has orders for over 1.7 billion doses. Bourla stated that he hopes low-income countries place orders as the company charges them less than those with higher incomes.

Pfizer stock shares rose over 4% Tuesday.